Comparative Pharmacology
Head-to-head clinical analysis: CHRONULAC versus POLYETHYLENE GLYCOL 3350.
Head-to-head clinical analysis: CHRONULAC versus POLYETHYLENE GLYCOL 3350.
CHRONULAC vs POLYETHYLENE GLYCOL 3350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic pH, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Osmotic laxative. Polyethylene glycol 3350 is a non-absorbable polymer that retains water in the colon via hydrogen bonding, increasing stool water content and stimulating defecation.
10-30 mL orally once daily to twice daily; for acute constipation, 20-30 mL initially; for hepatic encephalopathy, 30-60 mL every 1-2 hours to achieve 2-3 soft stools daily.
17 g (1 capful or packet) dissolved in 4–8 oz (120–240 mL) water, administered orally once daily for constipation; for colonoscopy preparation, 240 g (4 L of solution) ingested at 240 mL every 10–15 minutes.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Terminal elimination half-life is 1-2 hours in patients with normal renal function; prolonged in renal impairment, but clinical impact minimal due to primarily fecal elimination.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Renal: approximately 20% excreted unchanged; Fecal: approximately 80% eliminated unchanged in feces.
Category C
Category C
Osmotic Laxative
Osmotic Laxative